Economic burden of cardiovascular disease in the United Kingdom (UK).

Background And Aims: Direct (medical and non-medical) and indirect (production losses and informal care) costs of cardiovascular disease (CVD) have been captured in two previous United Kingdom (UK) cost-of-illness studies, but the areas of long-term care and medical device costs were neglected. We aimed to quantify the economic burden of CVD in the UK from a societal perspective between fiscal years 2019/20 to 2021/22.

Methods: Mixed-methods study in a prevalence-based retrospective review of economic costs focused on the public sector. Top-down costing was applied to the following areas: inpatient hospital care, outpatient specialist care, emergency care, primary care, medications, medical devices, long-term care, production losses to morbidity, and production losses to mortality. Bottom-up costing was used by applying the marginal effects of having a cardiovascular disease on several parameters using survey data from the Survey on Health, Aging, and Retirement in Europe to estimate informal care costs.

Results: The modelling performed shows that the total costs of CVD in the UK in 2021/22 were £29.021 billion (bn), with direct costs of £16.620 bn and indirect costs of £12.402 bn. The breakdown of direct costs for the UK were inpatient care (£6.732 bn), long-term care (£4.649 bn), medications (£1.940 bn), primary care (£1.556 bn), outpatient care (£1.011 bn), emergency care (£327.6 million (mn)), and medical devices (£404.4 mn). The breakdown of indirect costs for the UK were informal care costs (£6.377 bn), production losses to mortality (£4.544 bn), and production losses to morbidity (£1.481 bn).

Conclusion: There is a significant economic burden of CVD in the UK, with the highest direct cost resulting from inpatient care and the highest indirect cost resulting from informal care.